Healthcare & Biotech

SHERIDAN, WYOMING – May 19, 2025 – Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, has announced the successful completion of a $250 million strategic investment from global investment powerhouse KKR. The transaction marks a pivotal growth move, with KKR acquiring approximately 12% of Henry Schein’s common shares and strengthening its governance role with the appointment of two prominent executives to the company’s Board of Directors.

Strategic Growth Backed by Capital and Expertise

SHERIDAN, WYOMING - May 19, 2025 - Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, will present at the Jefferies Global Healthcare Conference on June 4, 2025. The event will be held at the Marriott Marquis in New York City, with Henry Schein's session scheduled for 1:20 p.m. Eastern Time.

This high-profile investor appearance underscores Henry Schein's continued momentum in delivering comprehensive health care solutions and showcases its strategic focus on long-term shareholder value, operational innovation, and global market leadership.

Highlighting Growth Strategy at a Premier Investor Forum

SHERIDAN, WYOMING – May 19, 2025 – Royal Philips has announced the European launch of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter, marking a significant step in transforming structural heart procedures through minimally invasive, real-time imaging technology. Already established in the U.S. market, this cutting-edge device supports more efficient, patient-friendly interventions without requiring general anesthesia — a major development for healthcare providers facing rising demands in structural heart disease care.

Revolutionizing Intracardiac Imaging and Clinical Workflows

VeriSight Pro introduces a miniaturized ultrasound probe at the tip of a steerable catheter, just 3 millimeters in diameter, enabling detailed 2D and 3D imaging directly inside the heart. This innovation allows physicians to perform complex interventions with increased confidence, streamlined workflows, and reduced procedural burden.

SHERIDAN, WYOMING – May 19, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the successful pricing of a €1 billion dual-tranche bond issuance under its European Medium Term Note (EMTN) program, marking a strategic step to reinforce its capital structure and advance sustainable investment goals.

The offering consists of €500 million in fixed-rate notes due 2030 and another €500 million in notes due 2035. This financial move is designed to refinance existing 2026 debt maturities and fund eligible green projects as defined in the company’s Sustainable Finance Framework. With significant investor interest, both tranches were heavily oversubscribed—by more than three times for the 2030 notes and more than four times for the 2035 notes—underscoring strong market confidence in Philips’ long-term strategy and ESG commitments.

Strategic Financial Optimization with ESG Integration

SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation has achieved a historic milestone in genomic medicine, enabling the development and delivery of the world’s first personalized mRNA-based CRISPR therapy for an infant with a life-threatening genetic disorder—in under six months. Powered by the Danaher Business System (DBS), this breakthrough exemplifies how disciplined innovation and cross-company collaboration can dramatically accelerate biopharmaceutical timelines and patient impact.

Compressing an 18-Month Timeline into Six

The urgency was real: an infant diagnosed with neonatal-onset CPS1 deficiency—a rare urea cycle disorder causing fatal ammonia accumulation—needed a cure in weeks, not years. DBS, Danaher’s proprietary system of operational tools and methodologies, allowed teams to strip away inefficiencies and take bold, calculated action.

SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation is reinforcing its position at the forefront of life sciences and diagnostics innovation through its Beacon program—an initiative designed to transform cutting-edge academic research into scalable, market-ready solutions. Spearheaded by Vanessa Almendro, PhD, MBA, Vice President, Head of Science and Technology Innovation at Danaher, the Beacon model exemplifies how strategic academic-industry collaboration can generate high-impact innovations aligned with real-world healthcare and biotechnology challenges.

A Structured Pathway from Discovery to Deployment

SHERIDAN, WYOMING – May 17, 2025 – Despite facing one of the most turbulent periods since the biotech industry’s inception in the 1970s, Danaher’s Chief Science Officer, Jose-Carlos Gutierrez-Ramos, believes the sector stands on the cusp of unprecedented progress. In a new commentary, Gutierrez-Ramos outlines why the healthcare and life sciences industries should remain optimistic, citing the explosive growth of GLP-1 receptor agonists, a rapidly evolving pipeline in Alzheimer’s research, and the transformative power of artificial intelligence.

GLP-1 Receptor Agonists Redefine Market Potential

One of the most significant advances highlighted is the rise of GLP-1 receptor agonists—initially developed for type II diabetes and now expanding rapidly into other indications. These therapies have gained broad consumer attention for their role in weight loss and obesity management, but their potential extends much further.

SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation is spotlighting the rapid progress and growing potential of RNA medicines, reaffirming its strategic commitment to genomic innovation while calling on industry stakeholders to sustain investment in the field. As RNA therapeutics expand across disease areas and delivery methods, Danaher’s leadership is urging the life sciences ecosystem to double down on momentum at what it describes as a defining moment for RNA-based medicine.

Breakthroughs in RNA Delivery and Safety Optimization

Among the most critical hurdles in RNA medicine—targeted delivery and toxicity—significant strides have been made. Lipid nanoparticle (LNP) technology has advanced in both in vivo and in vitro applications, bringing the field closer to achieving cell-type-specific delivery of therapeutic RNA molecules. This innovation promises enhanced safety and efficacy across a range of diseases.

SHERIDAN, WYOMING – May 15, 2025 – A groundbreaking new report from Royal Philips has unveiled the immense potential of artificial intelligence (AI) to transform healthcare as we know it—if healthcare systems, providers, and patients are willing to trust it. The Future Health Index (FHI) 2025 sheds light on a stark reality: millions of people worldwide are waiting months for care, and the pressure on overburdened health workers is at a breaking point. Yet, as this global crisis deepens, AI emerges as a hopeful solution ready to relieve stress, reduce delays, and bring healthcare into the future.

Long Waits, Lost Time, and Worsening Health

SHERIDAN, WYOMING – May 14, 2025 – As healthcare systems worldwide confront mounting environmental challenges linked to medical waste, Bertin Medical Waste is stepping forward with a scalable, award-winning solution that redefines how infectious waste is managed. The company’s Sterilwave system presents a timely, sustainable alternative to incineration, aligning operational efficiency with global environmental standards and helping drive healthcare infrastructure toward a more circular, resilient model.

Addressing a Post-Pandemic Waste Crisis